Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 1332, pseudogene (RNU6-1332P) is classified as a **pseudogene** derived from the U6 small nuclear RNA (snRNA) gene family[1][2]. U6 snRNA is an essential component of the spliceosome, involved in pre-mRNA splicing and highly conserved across eukaryotes, but pseudogenes such as RNU6-1332P do not produce functional RNA products and are considered non-coding[1][2][5]. They arise through genomic duplications or retrotransposition events and lose their original function due to mutations or truncations[2][5]. Due to its nature as a pseudogene, RNU6-1332P is **not a therapeutic target, drug receptor, enzyme, or biomarker** and has no established biological function, disease association, or known interacting drugs[1][2].\n\n**Note:**\n- This entry represents a non-functional pseudogene, not a protein, enzyme, receptor, or any established druggable target[1][2][5].\n- No evidence is present in the literature that links this pseudogene to disease or functional modulation.\n- Inclusion in target or drug discovery pipelines is not appropriate unless new evidence specifically establishes a functional or regulatory role.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1332, pseudogene (RNU6-1332P).